Skip to main content
. 2020 Oct 24;12(1):171–181. doi: 10.1007/s13300-020-00948-1

Table 1.

Baseline characteristics of the study participants

Baseline patient characteristics Lobeglitazone group (N = 104) Pioglitazone group (N = 101) P value**
Normoalbuminuria Micro-/macroalbuminuria P value* Normoalbuminuria Micro-/macroalbuminuria P value*
Age (years) 55.9 ± 10.8 57.0 ± 8.9 0.704 56.3 ± 12.8 59.0 ± 8.7 0.302 0.274
Male 35 (41.7) 8 (40.0) 1.000 31 (42.5) 19 (67.9) 0.039 0.302
Height (cm) 162.3 ± 7.6 160.3 ± 8.6 0.313 163.3 ± 10.7 160.3 ± 7.6 0.181 0.700
Weight (kg) 72.8 ± 13.7 65.2 ± 10.0 0.028 67.6 ± 16.1 64.4 ± 9.0 0.342 0.374
Body mass index (kg/m2) 27.6 ± 4.8 25.3 ± 3.0 0.052 25.0 ± 3.7 25.0 ± 2.8 0.957 0.112
Systolic blood pressure (mmHg) 130.0 ± 12.9 124.9 ± 13.7 0.132 128.3 ± 13.1 122.4 ± 15.7 0.064 0.363
Diastolic blood pressure (mmHg) 85.9 ± 8.7 80.4 ± 9.9 0.018 80.5 ± 10.0 77.1 ± 9.4 0.129 0.014
Diabetes duration (year) 6.6 ± 4.7 7.2 ± 5.2 0.599 7.3 ± 5.5 8.1 ± 6.1 0.523 0.328
Fasting plasma glucose (mg/dL) 163.9 ± 43.8 147.2 ± 37.2 0.128 167.2 ± 45.4 148.8 ± 30.2 0.055 0.514
HbA1c (%) 8.05 ± 0.54 7.81 ± 0.73 0.107 8.00 ± 0.67 7.89 ± 0.71 0.469 0.530
Total cholesterol (mg/dL) 165.6 ± 37.2 158.2 ± 34.5 0.428 174.3 ± 35.7 163.1 ± 35.7 0.166 0.197
Triglyceride (mg/dL) 152.1 ± 50.2 134.8 ± 74.7 0.224 199.5 ± 139.6 130.5 ± 63.1 0.017 0.333
HDL-cholesterol (mg/dL) 47.4 ± 9.0 49.8 ± 11.7 0.311 44.6 ± 11.2 48.9 ± 11.3 0.090 0.312
Creatinine (mg/dL) 0.74 ± 0.22 0.71 ± 0.20 0.485 0.80 ± 0.17 0.71 ± 0.16 0.021 0.375
eGFR (mL/min/1.73 m2) 95.7 ± 16.1 98.6 ± 13.9 0.463 94.6 ± 17.6 96.7 ± 12.3 0.558 0.331
UACR (mg/g Cr) 8.0 ± 5.9 115.1 ± 129.2 0.001 8.7 ± 6.8 209.4 ± 542.3 0.041 0.209
Normoalbuminuria 84 (100.0) 0 (0.0) < 0.001 73 (100.0) 0 (0.0) < 0.001 0.341
Microalbuminuria 0 (0.0) 19 (95.0) 0 (0.0) 26 (92.9)
Macroalbuminuria 0 (0.0) 1 (5.0) 0 (0.0) 2 (7.1)

Data are expressed as the mean ± standard deviation (SD) or as a number with the percentage in parentheses

Cr Creatinine, eGFR estimated glomerular filtration rate, HbA1c glycated hemoglobin, HDL high-density lipoprotein, UACR urine albumin-to-creatinine ratio

*Significant difference at P < 0.05 (normoalbuminuria vs. micro-/macroalbuminuria); **significant difference at P < 0.05 (lobeglitazone vs. pioglitazone)